Syndicate Bio — Seed — Dossier

One-Liner & Thesis

A biotech platform driving genomic and precision medicine initiatives across the world's most diverse regions to enable drug discovery. Syndicate Bio is building the world’s most diverse and richest human health datasets and applying AI/ML to usher in a new age of human discoveries and inclusive care globally.

StoryHouse is evaluating the Seed.

Founders

Estelle Dogbo

Estelle Dogbo at Syndicate Bio.

Jumi Popoola

Jumi Popoola at Syndicate Bio.

Abasi Ene-Obong

Nigerian-born biomedical scientist and entrepreneur with deep global healthcare experience. Holds a PhD in Cancer Biology, an MSc in Human Molecular Genetics, and has worked as a research scientist, management consultant, and biotech builder; previously co-founder and CEO of 54gene, where he helped build one of the largest genomic biobanks focused on African genetic diversity, and now leads Syndicate Bio to build the world's richest and most diverse human health datasets using AI/ML to advance inclusive discovery and precision medicine globally.

LinkedIn abasi@syndicate.bio

Open Questions & Risks

Three business units (genomics testing, therapeutics, data/IP) is broad for a seed — focus risk.
Africa market entry carries regulatory and operational complexity.
Radiopharma partnership terms (2 steering seats, 5% IP share) not yet closed.

Next Steps

Confirm the radiopharmaceutical partnership closes (expected within 1–2 weeks).
Resolve steering-committee representation and IP revenue-share terms.

Latest Meeting Notes

2026-05-26 Business model overview Precision-medicine infrastructure for Africa

Syndicate Bio is building integrated precision-medicine infrastructure for Africa across three units: clinical genomics testing, precision therapeutics (drug licensing), and data/IP licensing.

Thesis: ~20-year drug-launch delay from the US to Africa; most drugs arrive only as generics, biologics scarce (cetuximab reached Nigeria only two years ago).
Traction: Radiopharmaceutical partnership nearly finalized, expected to close within a week or two.
Open terms: Steering-committee seats (2 requested) and IP revenue share (5% of revenue after costs) still to resolve.

Source: Meeting Notes recvQRbvQ3yHulO4y

One-Liner & Thesis

Deal Box

Company Snapshot

Founders

Open Questions & Risks

Next Steps

Latest Meeting Notes

Deal Timeline